Tom von Gunden
Chief Editor Tom von Gunden provides the Drug Delivery Leader audience with indispensable resources for staying current on the drug and biologics delivery industry’s most innovative thinking. In addition to offering his written commentary and moderating events, Tom hosts multiple videocast series in which he and his guests illuminate challenges and advances in delivering medicines and therapies to an ever-widening landscape of patient needs and targets.
ARTICLES BY TOM VON GUNDEN
-
![2026 healthcare, insurance, wellness, medical concepts-GettyImages-2235662603]( "<em>Combination</em>: The Drug Delivery Word Of The Year For 2026")
12/30/2025In this article, Chief Editor Tom von Gunden explains why he sees 2026 as the year combination products and therapies become fully central to drug and biologics product development, delivery, and regulatory. He points to personalized medicine and patient self-administration as key factors shaping his view of the drug delivery landscape.
-
![Human Factors Panel bucket]( "Regulating For Patient Safety And Success With Combination Products")
12/16/2025At the AFDO/RAPS Combination Products Summit 2025, a notable focus emerged around approaches to risk assessment and human factors studies. In this article, Chief Editor Tom von Gunden offers his appreciation for the biopharma industry’s consideration of patient usability and safety in the development and regulation of combination products and other drug delivery devices.
-
![Halozyme patient panel]( "What Do Patients Appreciate? Therapeutic Innovation And Accessibility")
11/11/2025At the PODD 2025 conference, patient advocates telling their own treatment stories focused on innovations in therapies and delivery methods for targeting chronic and rare diseases, leveraging technologies such as gene editing and subcutaneous delivery of complex biologics. In this article, Chief Editor Tom von Gunden carries forward the patient-centric themes of convenience and accessibility.
